The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL
Abstract
RANKL is a TNF family member that mediates osteoclast formation, activation, and survival by activating RANK. The proresorptive effects of RANKL are prevented by binding to its soluble inhibitor osteoprotegerin (OPG). Recombinant human OPG-Fc recognizes RANKL from multiple species and reduced bone resorption and increased bone volume, density, and strength in a number of rodent models of bone disease. The clinical development of OPG-Fc was discontinued in favor of denosumab, a fully human monoclonal antibody that specifically inhibits primate RANKL. Direct binding assays showed that denosumab bound to human RANKL but not to murine RANKL, human TRAIL, or other human TNF family members. Denosumab did not suppress bone resorption in normal mice or rats but did prevent the resorptive response in mice challenged with a human RANKL fragment encoded primarily by the fifth exon of the RANKL gene. To create mice that were responsive to denosumab, knock-in technology was used to replace exon 5 from murine RANKL with its human ortholog. The resulting “huRANKL” mice exclusively express chimeric (human/murine) RANKL that was measurable with a human RANKL assay and that maintained bone resorption at slightly reduced levels versus wildtype controls. In young huRANKL mice, denosumab and OPG-Fc each reduced trabecular osteoclast surfaces by 95% and increased bone density and volume. In adult huRANKL mice, denosumab reduced bone resorption, increased cortical and cancellous bone mass, and improved trabecular microarchitecture. These huRANKL mice have potential utility for characterizing the activity of denosumab in a variety of murine bone disease models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationHsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Self-citationDenosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119 · cited 1×
“Denosumab and OPG are thought to function in a similar manner by binding RANKL and preventing it from activating its receptor (RANK), which is found on osteoclasts and osteoclast precursors.((6,7)) These data provide the first direct”
BackgroundSelf-citationKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Self-citationBekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746 · cited 1×
“Denosumab and OPG are thought to function in a similar manner by binding RANKL and preventing it from activating its receptor (RANK), which is found on osteoclasts and osteoclast precursors.((6,7)) These data provide the first direct”
BackgroundThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Self-citationBody, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1933 · Cited by 490
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Interactions of Tumor Necrosis Factor (TNF) and TNF Receptor Family Members in the Mouse and Human
Bossen, C., Ingold, K., Tardivel, A., Bodmer, J.-L., Gaide, O., Hertig, S., Ambrose, C., Tschopp, J., & Schneider, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601553200 · Cited by 443
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Lum, L., Wong, B. R., Josien, R., Becherer, J. D., Erdjument-Bromage, H., Schlöndorff, J., Tempst, P., Choi, Y., & Blobel, C. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13613 · Cited by 410
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64556-7 · Cited by 391
Self-citationBody, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281 · cited 7×
“RANKL is a key mediator of bone resorption, and the inhibition of RANKL by its soluble decoy receptor OPG results in suppression of bone resorption and increases in cortical and trabecular bone volume, density, and strength in mice, rats, and nonhuman primates.((18)) Recombinant”
BackgroundInfluentialSelf-citationOvariectomy-Induced Bone Loss Varies Among Inbred Strains of Mice
Bouxsein, M. L., Myers, K. S., Shultz, K. L., Donahue, L. R., Rosen, C. J., & Beamer, W. G. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050307 · Cited by 251
Temperature-sensitive Differential Affinity of TRAIL for Its Receptors
Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., Mclaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910438199 · Cited by 245
Green, L. L. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00137-4 · Cited by 229
Sedger, L. M., Glaccum, M. B., Schuh, J. C. L., Kanaly, S. T., Williamson, E., Kayagaki, N., Yun, T., Smolak, P. J., Le, T., Goodwin, R. G., et al. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200208)32:8<2246::aid-immu2246>3.0.co;2-6 · Cited by 208
RANKL Inhibition Through Osteoprotegerin Blocks Bone Loss in Experimental Periodontitis
Jin, Q., Cirelli, J. A., Park, C. H., Sugai, J. V., Taba, M., Kostenuik, P. J., & Giannobile, W. V. (2007) · Journal of Periodontology · doi:10.1902/jop.2007.070073 · Cited by 198
Self-citationCrystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity
Lam, J., Nelson, C. A., Ross, F. P., Teitelbaum, S. L., & Fremont, D. H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13890 · Cited by 194
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
Nakamura, M., Udagawa, N., Matsuura, S., Mogi, M., Nakamura, H., Horiuchi, H., Saito, N., Hiraoka, B. Y., Kobayashi, Y., Takaoka, K., et al. (2003) · Endocrinology · doi:10.1210/en.2003-0717 · Cited by 191
McDonald, M. M., Dulai, S. K., Godfrey, C., Amanat, N., Sztynda, T., & Little, D. G. (2008) · Bone · doi:10.1016/j.bone.2008.05.019 · Cited by 164
Xu, J., Tan, J. W., Huang, L., Gao, X.-H., Laird, R., Liu, D., Wysocki, S., & Zheng, M. H. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.11.2178 · Cited by 160
Shalhoub, V., Faust, J., Boyle, W. J., Dunstan, C. R., Kelley, M., Kaufman, S., Scully, S. A., Van, G. Y., & Lacey, D. L. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19990201)72:2<251::aid-jcb9>3.0.co;2-w · Cited by 137
Self-citationAkatsu, T., Murakami, T., Nishikawa, M., Ono, K., Shinomiya, N., Tsuda, E., Mochizuki, S.-I., Yamaguchi, K., Kinosaki, M., Higashio, K., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9294 · Cited by 123
Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C. R., Stouch, B., Martin, S., & Kostenuik, P. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.852 · Cited by 103
Self-citationStolina, M., Adamu, S., Ominsky, M., Dwyer, D., Asuncion, F., Geng, Z., Middleton, S., Brown, H., Pretorius, J., Schett, G., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050601 · Cited by 99
Self-citationMorony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1583 · Cited by 97
Self-citationRANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic Osteonecrosis
Kim, H. K., Morgan-Bagley, S., & Kostenuik, P. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060905 · Cited by 89
Self-citationSamadfam, R., Xia, Q., & Goltzman, D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060915 · Cited by 80
Lee, H., Zahra, D., Vogelzang, A., Newton, R. A., Thatcher, J., Quan, A., So, T., Zwirner, J., Köentgen, F., Padkjær, S. B., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1248 · Cited by 66
Byrne, F. R., Morony, S., Warmington, K., Geng, Z., Brown, H. L., Flores, S. A., Fiorino, M., Yin, S. L., Hill, D., Porkess, V., et al. (2004) · Gut · doi:10.1136/gut.2003.035113 · Cited by 66
Self-citationOminsky, M. S., Kostenuik, P. J., Cranmer, P., Smith, S. Y., & Atkinson, J. E. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0363-7 · Cited by 55
Self-citationUlrich-Vinther, M., & Andreassen, T. T. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0126-9 · Cited by 46 · cited 1×
“callus formation and positive effects on callus strength despite delays in callus remodeling.((46,47)) In summary, OPG and denosumab inhibit osteoclasto-”
BackgroundThe effects of osteoprotegerin on the mechanical properties of rat bone.
Ross, A. B., Bateman, T. A., Kostenuik, P. J., Ferguson, V. L., Lacey, D. L., Dunstan, C. R., & Simske, S. J. (2001) · Journal of Materials Science: Materials in Medicine · doi:10.1023/a:1011229324412 · Cited by 39
Self-citationPadagas, J., Colloton, M., Shalhoub, V., Kostenuik, P. J., Morony, S., Munyakazi, L., Guo, M., Gianneschi, D., Shatzen, E. M., Geng, Z., et al. (2005) · Calcified Tissue International · doi:10.1007/s00223-005-0161-1 · Cited by 38
Self-citationCloning and characterization of the gene encoding mouse osteoclast differentiation factor
Kodaira, K., Kodaira, K., Mizuno, A., Yasuda, H., Shima, N., Murakami, A., Ueda, M., & Higashio, K. (1999) · Gene · doi:10.1016/s0378-1119(99)00025-6 · Cited by 30
Expression and functional activity of osteoprotegerin in human malignant gliomas
Naumann, U., Wick, W., Beschorner, R., Meyermann, R., & Weller, M. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0772-4 · Cited by 23
Morony, S., Warmington, K. S., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M. S., Tan, H. L. E., Capparelli, C., Starnes, C. O., Dunstan, C. R., et al. (2005) · Cited by 13
Self-citation
Cited by
Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
Matrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304
“For example, administration of denosumab, a monoclonal antibody to human RANKL, to 10-month-old human RANKL knock-in mice increased femoral cancellous bone volume by almost twofold and decreased osteoclast surface by >95% (ref”
BackgroundDenosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 694
Self-citationA framework for the development of effective anti-metastatic agents
Anderson, R. L., Balasas, T., Callaghan, J., Coombes, R. C., Evans, J., Hall, J. A., Kinrade, S., Jones, D., Jones, P. S., Jones, R., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0134-8 · Cited by 341
Metadata
- Authors
- Kostenuik, P. J., Nguyen, H. Q., McCabe, J., Warmington, K. S., Kurahara, C., Sun, N., Chen, C., Li, L., Cattley, R. C., Van, G., Scully, S., Elliott, R., Grisanti, M., Morony, S., Tan, H. L., Asuncion, F., Li, X., Ominsky, M. S., Stolina, M., Dwyer, D., Dougall, W. C., Hawkins, N., Boyle, W. J., Simonet, W. S., & Sullivan, J. K.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-02-01
- Volume
- 24
- Issue
- 2
- Pages
- 182-195
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1985645291
- Cited by
- 443
- References
- 42
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.